Teva Gets Favorable Ruling Against Mylan in Azilect Generic Battle

A federal judge has upheld Teva’s patent for Azilect, striking down a claim from Mylan and possibly ending a long legal battle surrounding the Parkinson’s disease drug. Judge Claire C. Cecchi concluded that Mylan failed to prove by “clear and convincing evidence” that the patent was invalid for obviousness or for lack of enablement or utility.
Drug Industry Daily